CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TFA Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TFA Therapeutics, Inc.
6F, No.15, Lane 548
Rueiguang Road, Neihu District
Phone: +886 227489091p:+886 227489091 TAIPEI, 114  Taiwan Ticker: RAJAFRAJAF
Business Summary
TFA Therapeutics, Inc., formerly Cordyceps Sunshine Biotech Holdings Co., Ltd., is a company mainly engaged in the research and development of novel nonsteroidal anti-inflammatory drugs. The Company uses antrocin A as its core candidate molecule to develop anti-inflammatory drugs with steroid replacement potential. Its main research project is TFA-01, currently targeting canine osteoarthritis as its primary indication, with plans to subsequently evaluate its applications in feline chronic dentistry and dermatitis. The Company has also established a bacterial strain development, culture amplification, and related technology platform to support the research and development of its candidate drugs.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Chief Financial Officer, Director Szu HaoHuang 43 5/1/2020 5/1/2020
Director YenhungLiu 51 7/1/2022 7/1/2022

Business Names
Business Name
Chengdu Skyherb Biotechnology Co., Ltd.
RAJAF
Taiwanofungus Biotech Co. Ltd.

General Information
Number of Employees: 16 (As of 12/31/2025)
Outstanding Shares: 111,120,000 (As of 12/31/2025)
Shareholders: 92
Stock Exchange: OTC


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, November 1, 2026